SCHEMBL10076681

SCHEMBL10076681

COCCOc1cc(C)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 11/20 0.39
MAPT P10636 9/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 2/20 0.39
MAPK1 P28482 2/20 0.39
USP2 O75604 1/20 0.39
ALOX12 P18054 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 4/20 0.37
NPC1 O15118 3/20 0.37
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL4 Q8NA19 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19087000 0.87 CSF1R (0.34) L3MBTL1MAPTALDH1A1HPGDCYP2C9
SCHEMBL984465 0.84 SNCA (0.37) L3MBTL1ALDH1A1MAPK1NPSR1KDM4E
SCHEMBL26601625 0.82 MAPT (0.37) MAPTALDH1A1HPGDKMT2AMAPK1
SCHEMBL14315050 0.82 L3MBTL1 (0.40) L3MBTL1MAPTALDH1A1HPGDCYP2C9
SCHEMBL15334799 0.82 ACHE (0.47) L3MBTL1MAPTALDH1A1HPGDCYP2C9
SCHEMBL25796958 0.81 KDM4E (0.44) L3MBTL1MAPTALDH1A1HPGDMEN1
SCHEMBL262387 0.81 LPL (0.37) L3MBTL1MAPTALDH1A1HPGDNPSR1
SCHEMBL29534512 0.81 LPL (0.37) L3MBTL1MAPTALDH1A1HPGDNPSR1
SCHEMBL20745818 0.80 MEN1 (0.35) L3MBTL1MEN1KMT2ANPC1
SCHEMBL19491485 0.80 DGAT1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-11-30 US disclosed
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ENLIVEN INC. (US) 2023-11-07 US disclosed
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ENLIVEN INC. (US) 2023-09-26 US disclosed
US-20230130724-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-04-27 US disclosed
WO-2012040389-A2 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ABL1, ABL2, BCR L3MBTL1 1527/4885MAPT 4157/4885ALDH1A1 1397/4885
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR L3MBTL1 1527/4885MAPT 4157/4885ALDH1A1 1397/4885
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ABL1, ABL2, BCR L3MBTL1 1527/4885MAPT 4157/4885ALDH1A1 1397/4885
US-20230130724-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR L3MBTL1 1527/4885MAPT 4157/4885ALDH1A1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.